ERROR 404

Sorry. We couldn’t find this page for you.

It could be any of these reasons:

  • The URL isn’t spelled correctly.
  • This page has moved.
  • This page no longer exists.

Where would you like to return?

DUPIXENTHCP.com

For the Treatment of Adult and Pediatric Patients 6 Months and Older With Uncontrolled Moderate-to-Severe Atopic Dermatitis

Add-on Maintenance Treatment for Adult and Pediatric Patients 6 Years and Older With Moderate-to-Severe Eosinophilic or OCS‑Dependent Asthma

Add-on Maintenance Treatment for Adult Patients 18 Years and Older With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyposis

For the Treatment of Adult and Pediatric Patients Aged 1 Year and Older, Weighing at least 15kg, With Eosinophilic Esophagitis (EoE)

For the Treatment of Adult Patients 18 Years and Older With Prurigo Nodularis (PN)

DUPIXENT is indicated in:

  • Atopic Dermatitis: for the treatment of adult and pediatric patients aged 6 months and older with moderate‑to‑severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.
  • Asthma: as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate‑to‑severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.
  • Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP): as an add‑on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis.
  • Eosinophilic Esophagitis: for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).
  • Prurigo Nodularis: for the treatment of adult patients with prurigo nodularis (PN).